About Biomaxima
Biomaxima is a company based in Lublin (Poland) founded in 2002. Biomaxima has raised $111.31 thousand across 2 funding rounds. The company has 126 employees. Biomaxima offers products and services including Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials. Biomaxima operates in a competitive market with competitors including Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
- Headquarter Lublin, Poland
- Employees 126
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website biomaxima.com
- Social LinkedIn Facebook
- Legal Name Biomaxima Sa
- Annual Revenue$16.95 M (USD)15.24as on Dec 31, 2025
- Net Profit$29.23 K (USD)-80.37as on Dec 31, 2025
- EBITDA$993.78 K (USD)-5.85as on Dec 31, 2025
- Total Equity Funding$111.31K (USD)
in 2 rounds
- Latest Funding Round$150.02K (USD), Grant
Nov 2016
- Employee Count126
Products & Services of Biomaxima
Biomaxima offers a comprehensive portfolio of products and services, including Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials.
Tools for microbial testing in clinical and research labs
Kits for cell cultures and molecular analysis in laboratories
Products for disease detection and lab diagnostics
Single-use items for safe laboratory procedures
Funding Insights of Biomaxima
Biomaxima has successfully raised a total of $111.31K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $150.02 thousand completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $111,308
- Total Rounds 2
- Last Round Grant — $150,017
- First Round $111,308
(Apr 2010)
All 2 funding rounds of Biomaxima with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | $150,017 | Grant | – | – | – |
| Apr 2010 | $111,308 | Seed | – | – | – |
IPO & Listings of Biomaxima
Biomaxima is a publicly listed company on the GPW with ticker symbol BMX in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2010
- Listed onWSE: BMX
- Listed entityBiomaxima SA
- Exchange sectorHealth technology
- ISINPLBIOMX00015
- Share price10.06 PLN (+0.6% on the day) · 2026-10-09
- Market capitalisation41,931,181.00 PLN
- Price to earnings52.2
- EPS (diluted, trailing year)0.19 PLN
- Volume (last session)1,195
Financials of Biomaxima
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 60.9M PLN | 105,000 PLN | 3.6M PLN |
| 2024 | 52.9M PLN | 535,000 PLN | 3.8M PLN |
| 2023 | 46.8M PLN | 586,000 PLN | 1.9M PLN |
| 2022 | 143.9M PLN | 28.9M PLN | 36.8M PLN |
| 2021 | 79.1M PLN | 10.2M PLN | 13.1M PLN |
Detailed financial statements for Biomaxima
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Biomaxima
4 dated milestones of Biomaxima across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Biomaxima is founded.
- Funding First funding round of $111K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $150K.
Competitors of Biomaxima
Biomaxima operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| origene.com | 1996 | Rockville, United States | $69.55M | 141 | Proteins, antibodies, and molecular tools are manufactured for research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| caymanchem.com | 1980 | Ann Arbor, United States | – | 309 | Bioreagents and assay kits are developed, with preclinical services provided. | |
| abclonal.com | 2006 | Woburn, United States | $281.25M | – | Developer of protein and peptide reagents and kits for cell and molecular biology research | |
| seracare.com | 1984 | Milford, United States | – | – | Provider of biological materials/products that help optimize diagnostic performance, reliability and repeatability |
Detailed competitors of Biomaxima
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biomaxima
The website of Biomaxima (biomaxima.com) receives about 11.4K visits a month.
- Monthly visits11.4K
▼ 46.9% vs previous month
Websites whose visitors overlap most with Biomaxima. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
optometriakarczewski.pl | optometriakarczewski.pl | 100% | – | #10,976,727 | – |
Latest news on Biomaxima
Complete news archive for Biomaxima
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Biomaxima
10 companies that operate in the same segment as Biomaxima (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biomaxima
Biomaxima was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Biomaxima is headquartered in Lublin, Poland. It is registered at Lublin, Lublin Voivodeship, Poland.
Biomaxima is a funded company, having raised a total of $111.31K across 2 funding rounds to date. The company's 1st funding round was a Seed of $111.31K, raised on Apr 2010.
Biomaxima has 126 employees.
Annual revenue of Biomaxima is $16.95M as on Dec 31, 2025.
Biomaxima is engaged in the manufacturing and marketing of reagents for in vitro diagnostics.The companys product portfolio includes diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion selective analyzers and reagents, reagents and immunological analyzers of cardiac markers, glucometers for professional use, analysers for gasometric tests and critical blood parameters tests. It distributes its products in Poland and also exports to the markets of Lithuania, Latvia, Romania and France.
Biomaxima's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.
Biomaxima offers Microbiology Products, Molecular Biology Kits, Laboratory Diagnostics, and Disposable Materials.
Yes, Biomaxima is publicly traded on GPW under the ticker symbol BMX.
Biomaxima operates through Biomaxima Sa.